Apathy but Not Diminished Expression in Schizophrenia Is Associated with Discounting of Monetary Rewards by Physical Effort

Schizophrenia Bulletin

Volumn 41, Issue 2, 2015, Pages 503-512

  Hartmann, Matthias N ^a   Hager, Oliver M ^a   Reimann, Anna V ^a   Chumbley, Justin R ^a   Kirschner, Matthias ^a   Seifritz, Erich ^a   Tobler, Philippe N ^a   Kaiser, Stefan ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

cost benefit calculation; effort based decision making; negative symptoms

Indexed keywords

BENZODIAZEPINE; CHLORPROMAZINE; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; ZOLPIDEM;

ADULT; APATHY; ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DECISION MAKING; DEPRESSION; DISCOUNTING OF MONETARY REWARD; DISEASE ASSOCIATION; EDUCATIONAL STATUS; EXERCISE; FATIGUE; FEMALE; FOLLOW UP; GENERAL MENTAL DISEASE ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING; GROUP DYNAMICS; HAND GRIP; HUMAN; INCOME; INSOMNIA; LOW DRUG DOSE; MALE; MAXIMUM VOLUNTARY CONTRACTION; NEGATIVE SYNDROME; NERVOUS SYSTEM PARAMETERS; PATIENT ATTITUDE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REWARD; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SCHIZOPHRENIA ASSESSMENT; SELF REPORT; TASK PERFORMANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOSIS;

ADULT; APATHY; CHOICE BEHAVIOR; FEMALE; HUMANS; MALE; PHYSICAL EXERTION; PSYCHOTIC DISORDERS; REWARD; SCHIZOPHRENIA;

EID: 84940832681     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu102     Document Type: Article

References (55)

1. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495-506.
2. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147-150.
3. Fervaha G, Foussias G, Agid O, Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Res. 2013;210:665-668.
4. Faerden A, Finset A, Friis S, et al. Apathy in first episode psychosis patients: one year follow up. Schizophr Res. 2010;116:20-26.
5. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238-245.
6. Messinger JW, Trémeau F, Antonius D, et al. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev. 2011;31:161-168.
7. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36:359-369.
8. Liemburg E, Castelein S, Stewart R, et al. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res. 2013;47:718-725.
9. Brown RG, Pluck G. Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. Trends Neurosci. 2000;23:412-417.
10. Waltz JA, Frank MJ, Robinson BM, Gold JM. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry. 2007;62:756-764.
11. Koch K, Schachtzabel C, Wagner G, et al. Altered activation in association with reward-related trial-and-error learning in patients with schizophrenia. Neuroimage. 2010;50:223-232.
12. Simon JJ, Biller A, Walther S, et al. Neural correlates of reward processing in schizophrenia - relationship to apathy and depression. Schizophr Res. 2010;118:154-161.
13. Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull. 2008;34:835-847.
14. Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry. 2013;74:130-136.
15. Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Incentive motivation deficits in schizophrenia reflect effort computation impairments during costbenefit decision-making. J Psychiatr Res. 2013;47:1590-1596.
16. Fervaha G, Foussias G, Agid O, Remington G. Neural substrates underlying effort computation in schizophrenia. Neurosci Biobehav Rev. 2013;37:2649-2665.
17. Burke CJ, Brünger C, Kahnt T, Park SQ, Tobler PN. Neural integration of risk and effort costs by the frontal pole: only upon request. J Neurosci. 2013;33:1706-1713a.
18. Hasler G. Can the neuroeconomics revolution revolutionize psychiatry? Neurosci Biobehav Rev. 2012;36:64-78.
19. Kable JW, Glimcher PW. The neural correlates of subjective value during intertemporal choice. Nat Neurosci. 2007;10:1625-1633.
20. Hartmann MN, Hager OM, Tobler PN, Kaiser S. Parabolic discounting of monetary rewards by physical effort. Behav Processes. 2013;100:192-196.
21. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
22. BFS. Medizinische Statistik der Krankenhäuser: Anzahl Fälle und durchschnittliche Aufenthaltsdauer (DAD) nach Altersklasse und Diagnosekode. Neuchatel, Switzerland: BFS; 2012.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini- International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33; quiz 34-57.
25. Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37:300-305.
26. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
27. Frances A, Pincus HA, First MB. The Global Assessment of Functioning Scale (GAF). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
28. Schaub D, Juckel G. [PSP Scale: German version of the Personal and Social Performance Scale: valid instrument for the assessment of psychosocial functioning in the treatment of schizophrenia]. Nervenarzt. 2011;82:1178-1184.
29. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247-251.
30. Strauss GP, Hong LE, Gold JM, et al. Factor structure of the Brief Negative Symptom Scale. Schizophr Res. 2012;142:96-98.
31. Helmstaedter C, Lendt M, Lux S. VLMT. Verbaler Lern- und Merkfähigkeitstest. Göttingen, Germany: Beltz Test GmbH; 2001.
32. Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. Wechsler Memory Scale - Revised Edition, German Edition. Manual. Bern, Switzerland.: Huber; 2000.
33. Kessels RP, van Zandvoort MJ, Postma A, Kappelle LJ, de Haan EH. The Corsi Block-Tapping Task: standardization and normative data. Appl Neuropsychol. 2000;7:252-258.
34. Von Aster M, Neubauer A, Horn R. Wechsler Intelligenztest für Erwachsene WIE. Deutschsprachige Bearbeitung und Adaption des WAIS-III von David Wechsler. Frankfurt, Germany: Pearson Assessment; 2006.
35. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci. 1982;298:199-209.
36. Delis DC, Kaplan E, Kramer J. Delis Kaplan Executive Function System. San Antonio, TX: The Psychological Corporation; 2001.
37. Bickel WK, Marsch LA. Toward a behavioral economic understanding of drug dependence: delay discounting processes. Addiction. 2001;96:73-86.
38. Myerson J, Green L, Warusawitharana M. Area under the curve as a measure of discounting. J Exp Anal Behav. 2001;76:235-243.
39. Chen PY, Popovich PM. Correlation: Parametric and Nonparametric Measures. Thousand Oaks, CA: Sage; 2002.
40. Wetzels R, Wagenmakers EJ. A default Bayesian hypothesis test for correlations and partial correlations. Psychon Bull Rev. 2012;19:1057-1064.
41. Mueser KT, Sayers SL, Schooler NR, Mance RM, Haas GL. A multisite investigation of the reliability of the scale for the assessment of negative symptoms. Am J Psychiatr. 1994;151:1453-1462.
42. Sayers SL, Curran PJ, Mueser KT. Factor structure and construct validity of the scale for the assessment of negative symptoms. Psychological Assessment. 1996;8:269-280.
43. Jeffreys H. Theory of Probability. Oxford, England: Oxford University Press; 1961.
44. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
45. Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. 2012;66:77-92.
46. Mitchell SH. Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology (Berl). 1999;146:455-464.
47. Sescousse G, Redouté J, Dreher JC. The architecture of reward value coding in the human orbitofrontal cortex. J Neurosci. 2010;30:13095-13104.
48. Schmidt L, Lebreton M, Clery-Melin ML, Daunizeau J, Pessiglione M. Neural mechanisms underlying motivation of mental versus physical effort. Plos Biology. 2012;10:e1001266.
49. Barnes SA, Der-Avakian A, Markou A. Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol. 2014;24:744-758.
50. Markou A, Salamone JD, Bussey TJ, et al. Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia. Neurosci Biobehav Rev. 2013;37:2149-2165.
51. Salamone JD, Correa M, Nunes EJ, Randall PA, Pardo M. The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav. 2012;97:125-146.
52. Simpson EH, Waltz JA, Kellendonk C, Balsam PD. Schizophrenia in translation: dissecting motivation in schizophrenia and rodents. Schizophr Bull. 2012;38:1111-1117.
53. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008;199:331-388.
54. Alberati D, Moreau JL, Mory R, Pinard E, Wettstein JG. Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential. Pharmacol Biochem Behav. 2010;97:185-191.
55. Simpson EH, Kellendonk C, Ward RD, et al. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol Psychiatry. 2011;69:928-935.